Roche’s Burgess to head up discovery at BMS
pharmafile | January 18, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | BMS, Burgess
Bristol-Myers Squibb has appointed Mike Burgess as senior vice president, Discovery Medicine and Clinical Pharmacology.
He will report to Francis Cuss, senior vice president, Research, R&D at Bristol-Myers Squibb, and will be a member of the Research Senior Leadership Team.
“As a physician scientist with a Ph.D. in molecular biology, clinical experience in paediatrics and paediatric oncology, and extensive pharmaceutical industry and leadership experience, I believe Mike will be an important addition to our research and development organisation,” said Dr Cuss.
Burgess leaves his post as interim head of Roche’s Pharma Research and Early Development. Prior to that he led the Roche Oncology Discovery and Translational Area, one of five disease-focused organisations, and at the same time served as head of Global Large Molecule Research.
Prior to joining Roche in 2006, Burgess was at Eli Lilly as a Medical Fellow. He received his medical training and Ph.D. from the University of Bristol in the UK, and is a member of the Royal College of Physicians and of the Royal College of Paediatrics and Child Health.
“I am excited by the opportunity to join Bristol-Myers Squibb and its Research Leadership Team,” said Dr Burgess. “Bristol-Myers Squibb is well known and respected for its innovative pipeline and approach to discovering and developing new medicines. I am looking forward to joining this committed team and continuing to drive research that delivers a differentiated pipeline of potential new medicines.”
Related Content
BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer
Bristol Myers Squibb (BMS) has announced that its Opdivo (nivolumab) has been accepted, in combination …
Elekta and BMS partner for digital treatment for melanoma
Elekta and Bristol Myers Squibb have announced a pilot collaboration in which the companies plan …
BMS acquires Mirati Therapeutics for $4.8bn
Bristol Myers Squibb (BMS) and Mirati Therapeutics have announced that they have entered into a …
